COLO-PREVENT
Clinical samples collected from participants in COLO-PREVENT, a world first trial platform in prevention that consists of a main phase 3 study comparing aspirin alone versus aspirin plus metformin, and a phase 2 signal seeking trial of resveratrol, conducted in high-risk patients recruited through the NHS Bowel Cancer Screening Programme. The phase 3 trial is a 3 year intervention with aspirin/metformin and the phase 2 trial is a 1 year intervention comparing low and high dose resveratrol against placebo. The following samples are being collected and are being stored and analysed as part of the COLO-PREVENT translational programme: 1) Plasma and serum collected at baseline, 6 monthly intervals and the end of the trial. 2) Fresh frozen and formalin fixed paraffin embedded biopsies of normal rectal tissue taken at the end of the trial. 3) FFPE diagnostic samples of colorectal polyps taken as part of the initial screening colonoscopy and any polyps removed during the surveillance colonoscopy at the end of the trial. 4) Faecal samples collected using a FIT kit, at baseline, 1 year (for the main trial) and study end. These will be completely used for microbiome analysis. 5) Urine samples from a proportion of patients in the phase 2 resveratrol signal seeking trial.
Contact Information
- Email:
- kb20@le.ac.uk
- Telephone:
- 0116 2231851
- Address:
-
Leicester Cancer Research Centre
5th Floor Robert Kilpatrick Clinical Sciences Building
Leicester Royal Infirmary
University of Leicester
Leicester
Leicestershire
LE2 7LX
England
Last Updated: 05/01/2024
Annual Statistics
Year | Access Requests Received | Access Requests Approved | ||||
---|---|---|---|---|---|---|
Internal | External | Commercial | Internal | External | Commercial | |
2015 | N/A | N/A | N/A | N/A | N/A | N/A |
2016 | N/A | N/A | N/A | N/A | N/A | N/A |
2017 | N/A | N/A | N/A | N/A | N/A | N/A |
2018 | N/A | N/A | N/A | N/A | N/A | N/A |
2019 | N/A | N/A | N/A | N/A | N/A | N/A |
2020 | N/A | N/A | N/A | N/A | N/A | N/A |
2021 | N/A | N/A | N/A | N/A | N/A | N/A |
2022 | N/A | N/A | N/A | N/A | N/A | N/A |
2023 | N/A | N/A | N/A | N/A | N/A | N/A |
2024 | N/A | N/A | N/A | N/A | N/A | N/A |